Francis Medical Highlights Clinical Trial Progress for Vanquish Prostate Ablation System

According to a recent LinkedIn post from Francis Medical, the company is highlighting its engagement with the urology community at the European Association of Urology Congress 2026. The post centers on a dinner event where clinical insights from the VAPOR 2 Study were discussed, focusing on patient experience outcomes.

The LinkedIn post notes that VAPOR 2 is a novel, multi-center trial evaluating the Vanquish Water Vapor Ablation System, a transurethral thermal water vapor technique for ablating prostate tissue. Early data from the first 110 patients at 12-month follow-up are referenced as being available, suggesting a progression in the evidence base for this technology.

The post also points out that Vanquish is FDA cleared and positioned as an emerging, evidence-based approach to prostate care. For investors, the emphasis on clinical trial progress and professional engagement may indicate ongoing efforts to build physician awareness and adoption, which could be important for future revenue growth and competitive positioning in minimally invasive urology.

Continued dissemination of 12‑month follow-up data may help clarify the system’s safety and efficacy profile relative to existing treatments, potentially influencing reimbursement, guideline inclusion, and market access over time. If the clinical and patient experience outcomes prove favorable, Francis Medical could strengthen its niche within the prostate treatment market and enhance its long-term commercialization prospects.